Latest Insider Transactions at Kala Pharmaceuticals, Inc. (KALA)
This section provides a real-time view of insider transactions for Kala Pharmaceuticals, Inc. (KALA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kala Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kala Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2021
|
Mark T Iwicki CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,586
-2.5%
|
$37,930
$5.77 P/Share
|
|
Jun 28
2021
|
Todd Bazemore |
SELL
Open market or private sale
|
Direct |
2,911
-2.12%
|
$14,555
$5.77 P/Share
|
|
Jun 28
2021
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,452
-1.66%
|
$12,260
$5.77 P/Share
|
|
Jun 28
2021
|
Eric Trachtenberg |
SELL
Open market or private sale
|
Direct |
2,452
-1.91%
|
$12,260
$5.77 P/Share
|
|
Jun 28
2021
|
Romulus K Brazzell |
SELL
Open market or private sale
|
Direct |
3,034
-1.0%
|
$15,170
$5.77 P/Share
|
|
Jun 28
2021
|
Hongming Chen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,452
-1.01%
|
$12,260
$5.77 P/Share
|
|
Jun 17
2021
|
Gregory Grunberg |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+33.33%
|
-
|
|
Jun 17
2021
|
Andrew I Koven |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+32.05%
|
-
|
|
Jun 17
2021
|
Robert Bradley Paull |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+33.33%
|
-
|
|
Jun 17
2021
|
Gregory D Perry |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+33.33%
|
-
|
|
Jun 17
2021
|
Howard B Rosen |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+30.85%
|
-
|
|
Jun 17
2021
|
Rajeev M. Shah |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Apr 01
2021
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
1,687,709
+30.86%
|
$10,126,254
$6.74 P/Share
|
|
Mar 01
2021
|
Hongming Chen CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,500
+3.76%
|
$19,000
$2.3 P/Share
|
|
Feb 25
2021
|
Hongming Chen CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
47,000
+16.75%
|
$94,000
$2.3 P/Share
|
|
Jan 04
2021
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
22,666
+13.28%
|
-
|
|
Jan 04
2021
|
Mark T Iwicki CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
76,000
+20.01%
|
-
|
|
Jan 04
2021
|
Todd Bazemore |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+16.67%
|
-
|
|
Jan 04
2021
|
Eric Trachtenberg |
BUY
Grant, award, or other acquisition
|
Direct |
22,666
+14.99%
|
-
|
|
Jan 04
2021
|
Hongming Chen CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
22,666
+10.84%
|
-
|
|
Jan 04
2021
|
Romulus K Brazzell |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+8.3%
|
-
|
|
Oct 26
2020
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
61,000
+32.74%
|
-
|
|
Oct 26
2020
|
Mark T Iwicki CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
178,300
+43.9%
|
-
|
|
Oct 26
2020
|
Romulus K Brazzell |
BUY
Grant, award, or other acquisition
|
Direct |
81,000
+22.66%
|
-
|
|
Oct 26
2020
|
Hongming Chen CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
61,000
+27.13%
|
-
|
|
Oct 26
2020
|
Eric Trachtenberg |
BUY
Grant, award, or other acquisition
|
Direct |
61,000
+36.55%
|
-
|
|
Oct 26
2020
|
Todd Bazemore |
BUY
Grant, award, or other acquisition
|
Direct |
81,000
+42.41%
|
-
|
|
Oct 22
2020
|
Todd Bazemore |
BUY
Open market or private purchase
|
Indirect |
40
+48.78%
|
$280
$7.6 P/Share
|
|
Jun 05
2020
|
Todd Bazemore |
BUY
Open market or private purchase
|
Indirect |
2
+50.0%
|
$26
$13.39 P/Share
|
|
Mar 13
2020
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
6,337,135
+36.82%
|
$44,359,945
$7.89 P/Share
|
|
Oct 03
2018
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,424,242
+34.82%
|
$19,393,936
$8.25 P/Share
|
|
Feb 08
2018
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.72%
|
$300,000
$12.93 P/Share
|
|
Feb 02
2018
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
37,840
+1.09%
|
$529,760
$14.73 P/Share
|
|
Feb 01
2018
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
22,840
+0.67%
|
$319,760
$14.99 P/Share
|
|
Jan 31
2018
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
339,400
+9.17%
|
$5,091,000
$15.0 P/Share
|
|
Jan 29
2018
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
50,000
+1.63%
|
$700,000
$14.99 P/Share
|
|
Jan 26
2018
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
22,760
+0.76%
|
$318,640
$14.93 P/Share
|
|
Jan 24
2018
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
64,637
+2.14%
|
$904,918
$14.91 P/Share
|
|
Jan 23
2018
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,363
+0.15%
|
$61,082
$14.99 P/Share
|
|
Jan 22
2018
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
75,000
+2.54%
|
$1,050,000
$14.98 P/Share
|
|
Jan 19
2018
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
74,931
+2.6%
|
$1,049,034
$14.95 P/Share
|
|
Jan 12
2018
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
66,800
+1.22%
|
$935,200
$14.95 P/Share
|
|
Jan 11
2018
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
41,700
+1.54%
|
$542,100
$13.65 P/Share
|
|
Jan 10
2018
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
170,338
+6.1%
|
$2,044,056
$12.83 P/Share
|